Cleancard
Cleancard makes cancer screening as simple as a home pregnancy test by enabling rapid, lab-grade detection from urine. The company combines synthetic biology sensors with artificial intelligence analysis to detect and track biomarkers from a urine sample in about 30 minutes. Cleancard operates as a consumer-facing at-home diagnostics platform that delivers rapid screens for specific cancers using a single-sample workflow. Its platform approach allows the company to expand the panel of detectable conditions, currently including prostate, bladder, and ovarian cancers.
Cleancard
Cleancard makes cancer screening as simple as a home pregnancy test by enabling rapid, lab-grade detection from urine. The company combines synthetic biology sensors with artificial intelligence analysis to detect and track biomarkers from a urine sample in about 30 minutes. Cleancard operates as a consumer-facing at-home diagnostics platform that delivers rapid screens for specific cancers using a single-sample workflow. Its platform approach allows the company to expand the panel of detectable conditions, currently including prostate, bladder, and ovarian cancers.
TL;DR
What they do: At‑home, urine‑based rapid cancer screening using synthetic biology sensors + AI (~30-minute, lab‑grade detection)
Founded: 2021
Headquarters: London, United Kingdom
Founders: Luca Springer; Thomas Carroll
Funding stage: Pre‑Seed (reported Sep 1, 2023)
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Early cancer detection and at‑home diagnostics
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
Reported pre‑seed round with multiple investors
Investor Signal
“TQ Ventures; Urban Innovation Fund; Y Combinator”